Access is now shaping commercial performance. Learn how policy, payer dynamics, and evidence are redefining access strategy and what it requires from organizations today.
Market access ecosystem mapping helps biopharma teams move from identifying stakeholders to understanding how influence operates across the access landscape, enabling more coordinated engagement, stronger alignment, and more informed decision-making.
Regulatory approval does not guarantee payer coverage. As reimbursement decisions increasingly depend on comparative value, budget impact, and real-world evidence, integrating HEOR and payer considerations into clinical trial design can help biopharma teams anticipate access challenges and support stronger reimbursement discussions at launch.
How AI-driven EMR analysis helped identify high-risk cardiovascular patients and support earlier intervention.
How a biotechnology company used real-world data analysis to uncover cost drivers and validate the economic impact of EVLP.
Real-world evidence is no longer just a regulatory checkbox—it’s a strategic driver of pricing, access, and payer engagement. Discover how leading life sciences teams are embedding RWE earlier to shape reimbursement strategy, optimize launch planning, and unlock value-based contracts.
As policy dynamics accelerate across federal and state channels, manufacturers must prepare for multiple scenarios and align internal planning. Key readiness priorities for 2026.
Design research payers can use: focus on real-world outcomes, durability, and total cost of care; bring payer input in early and often; and pressure-test access levers pre-launch. Turn strong science into coverage, reimbursement, and measurable ROI.
In this featured presentation from the 2025 Evidence 360 Summit, Magnolia Market Access’s Beni Turner explores how RWE can be strategically integrated across the product lifecycle to drive more effective pricing and access outcomes.
This case study explores how a small pharmaceutical company utilized real-world evidence (RWE) to calculate the national incidence of a rare disease.